Cargando…

The influence of tumour necrosis factor α inhibitors treatment – etanercept on serum concentration of biomarkers of inflammation and cartilage turnover in psoriatic arthritis patients

INTRODUCTION: Effective treatment in psoriatic arthritis (PsA) patients can protect them from severe musculoskeletal complications. For appropriate monitoring of anti-tumour necrosis factor α (anti-TNF-α) treatment in PsA, specific biomarkers are needed. AIM: To investigate whether biological treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Waszczykowski, Michał, Bednarski, Igor, Lesiak, Aleksandra, Waszczykowska, Elżbieta, Narbutt, Joanna, Fabiś, Jarosław
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7874864/
https://www.ncbi.nlm.nih.gov/pubmed/33603621
http://dx.doi.org/10.5114/ada.2020.96705
_version_ 1783649674378346496
author Waszczykowski, Michał
Bednarski, Igor
Lesiak, Aleksandra
Waszczykowska, Elżbieta
Narbutt, Joanna
Fabiś, Jarosław
author_facet Waszczykowski, Michał
Bednarski, Igor
Lesiak, Aleksandra
Waszczykowska, Elżbieta
Narbutt, Joanna
Fabiś, Jarosław
author_sort Waszczykowski, Michał
collection PubMed
description INTRODUCTION: Effective treatment in psoriatic arthritis (PsA) patients can protect them from severe musculoskeletal complications. For appropriate monitoring of anti-tumour necrosis factor α (anti-TNF-α) treatment in PsA, specific biomarkers are needed. AIM: To investigate whether biological treatment with anti-TNF-α (etanercept 50 mg once a week subcutaneously) affects the activity of selected mediators of inflammation and destruction of articular cartilage: interleukin-6 (IL-6), interleukin-18 (IL-18), matrix metalloproteinases 1 and 3 (MMP-1, MMP-3), cartilage oligomeric matrix protein (COMP), human cartilage glycoprotein (YKL-40) in serum of patients with PsA. MATERIAL AND METHODS: The study included 25 patients with PsA. The concentration of IL-6, IL-18, MMP-1, MMP-3, COMP and YKL-40 in serum was determined before, and 6 and 12 weeks after the beginning of anti-TNF-α treatment. Clinical severity of the disease according to the Body Surface Area, Psoriasis Area and Severity Index and Dermatology Life Quality Index as well as tender and swollen joint count (TJC, SJC) were also evaluated. RESULTS: The study disclosed a statistically significant reduction in the serum concentration of IL-6, MMP-1 and YKL-40 in PsA patients after 6 and 12 weeks from the beginning of anti-TNF-α treatment (p = 0.00018 for IL-6; p = 0.01242 for MMP-1; p = 0.03263 for YKL-40). CONCLUSIONS: IL-6, MMP-1 and YKL-40 may be useful for monitoring the effectiveness of anti-TNF-α treatment.
format Online
Article
Text
id pubmed-7874864
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-78748642021-02-17 The influence of tumour necrosis factor α inhibitors treatment – etanercept on serum concentration of biomarkers of inflammation and cartilage turnover in psoriatic arthritis patients Waszczykowski, Michał Bednarski, Igor Lesiak, Aleksandra Waszczykowska, Elżbieta Narbutt, Joanna Fabiś, Jarosław Postepy Dermatol Alergol Original Paper INTRODUCTION: Effective treatment in psoriatic arthritis (PsA) patients can protect them from severe musculoskeletal complications. For appropriate monitoring of anti-tumour necrosis factor α (anti-TNF-α) treatment in PsA, specific biomarkers are needed. AIM: To investigate whether biological treatment with anti-TNF-α (etanercept 50 mg once a week subcutaneously) affects the activity of selected mediators of inflammation and destruction of articular cartilage: interleukin-6 (IL-6), interleukin-18 (IL-18), matrix metalloproteinases 1 and 3 (MMP-1, MMP-3), cartilage oligomeric matrix protein (COMP), human cartilage glycoprotein (YKL-40) in serum of patients with PsA. MATERIAL AND METHODS: The study included 25 patients with PsA. The concentration of IL-6, IL-18, MMP-1, MMP-3, COMP and YKL-40 in serum was determined before, and 6 and 12 weeks after the beginning of anti-TNF-α treatment. Clinical severity of the disease according to the Body Surface Area, Psoriasis Area and Severity Index and Dermatology Life Quality Index as well as tender and swollen joint count (TJC, SJC) were also evaluated. RESULTS: The study disclosed a statistically significant reduction in the serum concentration of IL-6, MMP-1 and YKL-40 in PsA patients after 6 and 12 weeks from the beginning of anti-TNF-α treatment (p = 0.00018 for IL-6; p = 0.01242 for MMP-1; p = 0.03263 for YKL-40). CONCLUSIONS: IL-6, MMP-1 and YKL-40 may be useful for monitoring the effectiveness of anti-TNF-α treatment. Termedia Publishing House 2020-07-14 2020-12 /pmc/articles/PMC7874864/ /pubmed/33603621 http://dx.doi.org/10.5114/ada.2020.96705 Text en Copyright: © 2020 Termedia Sp. z o. o. http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle Original Paper
Waszczykowski, Michał
Bednarski, Igor
Lesiak, Aleksandra
Waszczykowska, Elżbieta
Narbutt, Joanna
Fabiś, Jarosław
The influence of tumour necrosis factor α inhibitors treatment – etanercept on serum concentration of biomarkers of inflammation and cartilage turnover in psoriatic arthritis patients
title The influence of tumour necrosis factor α inhibitors treatment – etanercept on serum concentration of biomarkers of inflammation and cartilage turnover in psoriatic arthritis patients
title_full The influence of tumour necrosis factor α inhibitors treatment – etanercept on serum concentration of biomarkers of inflammation and cartilage turnover in psoriatic arthritis patients
title_fullStr The influence of tumour necrosis factor α inhibitors treatment – etanercept on serum concentration of biomarkers of inflammation and cartilage turnover in psoriatic arthritis patients
title_full_unstemmed The influence of tumour necrosis factor α inhibitors treatment – etanercept on serum concentration of biomarkers of inflammation and cartilage turnover in psoriatic arthritis patients
title_short The influence of tumour necrosis factor α inhibitors treatment – etanercept on serum concentration of biomarkers of inflammation and cartilage turnover in psoriatic arthritis patients
title_sort influence of tumour necrosis factor α inhibitors treatment – etanercept on serum concentration of biomarkers of inflammation and cartilage turnover in psoriatic arthritis patients
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7874864/
https://www.ncbi.nlm.nih.gov/pubmed/33603621
http://dx.doi.org/10.5114/ada.2020.96705
work_keys_str_mv AT waszczykowskimichał theinfluenceoftumournecrosisfactorainhibitorstreatmentetanerceptonserumconcentrationofbiomarkersofinflammationandcartilageturnoverinpsoriaticarthritispatients
AT bednarskiigor theinfluenceoftumournecrosisfactorainhibitorstreatmentetanerceptonserumconcentrationofbiomarkersofinflammationandcartilageturnoverinpsoriaticarthritispatients
AT lesiakaleksandra theinfluenceoftumournecrosisfactorainhibitorstreatmentetanerceptonserumconcentrationofbiomarkersofinflammationandcartilageturnoverinpsoriaticarthritispatients
AT waszczykowskaelzbieta theinfluenceoftumournecrosisfactorainhibitorstreatmentetanerceptonserumconcentrationofbiomarkersofinflammationandcartilageturnoverinpsoriaticarthritispatients
AT narbuttjoanna theinfluenceoftumournecrosisfactorainhibitorstreatmentetanerceptonserumconcentrationofbiomarkersofinflammationandcartilageturnoverinpsoriaticarthritispatients
AT fabisjarosław theinfluenceoftumournecrosisfactorainhibitorstreatmentetanerceptonserumconcentrationofbiomarkersofinflammationandcartilageturnoverinpsoriaticarthritispatients
AT waszczykowskimichał influenceoftumournecrosisfactorainhibitorstreatmentetanerceptonserumconcentrationofbiomarkersofinflammationandcartilageturnoverinpsoriaticarthritispatients
AT bednarskiigor influenceoftumournecrosisfactorainhibitorstreatmentetanerceptonserumconcentrationofbiomarkersofinflammationandcartilageturnoverinpsoriaticarthritispatients
AT lesiakaleksandra influenceoftumournecrosisfactorainhibitorstreatmentetanerceptonserumconcentrationofbiomarkersofinflammationandcartilageturnoverinpsoriaticarthritispatients
AT waszczykowskaelzbieta influenceoftumournecrosisfactorainhibitorstreatmentetanerceptonserumconcentrationofbiomarkersofinflammationandcartilageturnoverinpsoriaticarthritispatients
AT narbuttjoanna influenceoftumournecrosisfactorainhibitorstreatmentetanerceptonserumconcentrationofbiomarkersofinflammationandcartilageturnoverinpsoriaticarthritispatients
AT fabisjarosław influenceoftumournecrosisfactorainhibitorstreatmentetanerceptonserumconcentrationofbiomarkersofinflammationandcartilageturnoverinpsoriaticarthritispatients